Page 1 | Search Results | Blood | American Society of Hematology

1-6 of 6

Sort by

Sort Order Select

Journal Articles

The Effect of Paraprotein Heavy Chain and Free Light Chain Types on the Efficacy of Pegylated Liposomal Doxorubicin + Bortezomib Versus Bortezomib Alone in Patients with Relapsed/Refractory Multiple Myeloma

Jatin Shah, MD, Joan Blade, MD, Pieter Sonneveld, MD, PhD, Jesus San Miguel, MD, Donghan Luo, PhD, Keith C Lantz, MS, Colin Lowery, PhD, Jean-Luc Harousseau, MD, Robert Z. Orlowski, MD, PhD

Blood (2008) 112 (11): 5190.

https://doi.org/10.1182/blood.V112.11.5190.5190

Published: 2008

Journal Articles

The Effect of Bone Marrow Involvement on the Efficacy of Pegylated Liposomal Doxorubicin + Bortezomib Vs Bortezomib Alone in Patients with Relapsed/Refractory Multiple Myeloma

Jatin Shah, MD, Joan Blade, MD, Jesus San Miguel, MD, Pieter Sonneveld, MD, PhD, Donghan Luo, PhD, Keith C Lantz, MS, Colin Lowery, PhD, Jean-Luc Harousseau, MD, Robert Z. Orlowski, MD, PhD

Blood (2008) 112 (11): 5192.

https://doi.org/10.1182/blood.V112.11.5192.5192

Published: 2008

Journal Articles

Early Normalization of Serum Free Light Chain Is Associated with Prolonged Time to Progression Following Bortezomib ± Pegylated Liposomal Doxorubicin Treatment of Relapsed/Refractory Multiple Myeloma.

Robert Orlowski, MD, PhD, Heather Sutherland, MD, PhD, Joan Bladé, MD, Jesús San Miguel, MD, Roman Hájek, MD, PhD, Arnon Nagler, MD, MSc, Pieter Sonneveld, MD, PhD, Andrew Spencer, DM, Tadeusz Robak, MD, PhD, Suneel Mundle, PhD, Donghan Luo, PhD, Sen Hong Zhuang, MD, PhD, Jean-Luc Harousseau, MD

Blood (2007) 110 (11): 2735.

https://doi.org/10.1182/blood.V110.11.2735.2735

Published: 2007

Journal Articles

Investigation of Epoetin alfa (EPO) 80,000 Units (U) Every 4 Weeks (Q4W) vs. 40,000 U Every 2 Weeks (Q2W) in Patients with Cancer Not Receiving Chemotherapy (CT) or Radiation Therapy (RT): Final Results.

Daniel Shasha, MD, Fitzroy Dawkins, MD, Donghan Luo, PhD, Francois E. Wilhelm, MD, PhD, MSc, Marc Kamin, MD

Blood (2007) 110 (11): 3775.

https://doi.org/10.1182/blood.V110.11.3775.3775

Published: 2007

Journal Articles

Early vs Standard Intervention with an Extended Epoetin alfa (EPO) Dose Regimen of 120,000 Units (U) Every 3 Weeks (Q3W) in Chemotherapy (CT)-Induced Anemia: Results for Elderly vs. Younger Patients in a Randomized Clinical Trial.

Veena Charu, MD, Victor Moyo, MD, Donghan Luo, PhD, Francois E. Wilhelm, MD, PhD, MSc

Blood (2007) 110 (11): 3769.

https://doi.org/10.1182/blood.V110.11.3769.3769

Published: 2007

Journal Articles

Erythroid Response to Epoetin alfa (EPO) 120,000 Units (U) Every Three Weeks (Q3W) Initiated Early or at a Standard Threshold in Chemotherapy-Induced Anemia (CIA).

Veena Charu, MD, Victor Moyo, MD, Donghan Luo, PhD, Francois E. Wilhelm, MD, PhD, MSc

Blood (2007) 110 (11): 3770.

https://doi.org/10.1182/blood.V110.11.3770.3770

Published: 2007

NARROW

The Effect of Paraprotein Heavy Chain and Free Light Chain Types on the Efficacy of Pegylated Liposomal Doxorubicin + Bortezomib Versus Bortezomib Alone in Patients with Relapsed/Refractory Multiple Myeloma

The Effect of Bone Marrow Involvement on the Efficacy of Pegylated Liposomal Doxorubicin + Bortezomib Vs Bortezomib Alone in Patients with Relapsed/Refractory Multiple Myeloma

Early Normalization of Serum Free Light Chain Is Associated with Prolonged Time to Progression Following Bortezomib ± Pegylated Liposomal Doxorubicin Treatment of Relapsed/Refractory Multiple Myeloma.

Investigation of Epoetin alfa (EPO) 80,000 Units (U) Every 4 Weeks (Q4W) vs. 40,000 U Every 2 Weeks (Q2W) in Patients with Cancer Not Receiving Chemotherapy (CT) or Radiation Therapy (RT): Final Results.

Early vs Standard Intervention with an Extended Epoetin alfa (EPO) Dose Regimen of 120,000 Units (U) Every 3 Weeks (Q3W) in Chemotherapy (CT)-Induced Anemia: Results for Elderly vs. Younger Patients in a Randomized Clinical Trial.

Erythroid Response to Epoetin alfa (EPO) 120,000 Units (U) Every Three Weeks (Q3W) Initiated Early or at a Standard Threshold in Chemotherapy-Induced Anemia (CIA).

Email alerts

ASH Publications

American Society of Hematology

The Effect of Paraprotein Heavy Chain and Free Light Chain Types on the Efficacy of Pegylated Liposomal Doxorubicin + Bortezomib Versus Bortezomib Alone in Patients with Relapsed/Refractory Multiple Myeloma

The Effect of Bone Marrow Involvement on the Efficacy of Pegylated Liposomal Doxorubicin + Bortezomib Vs Bortezomib Alone in Patients with Relapsed/Refractory Multiple Myeloma

Early Normalization of Serum Free Light Chain Is Associated with Prolonged Time to Progression Following Bortezomib ± Pegylated Liposomal Doxorubicin Treatment of Relapsed/Refractory Multiple Myeloma.

Investigation of Epoetin alfa (EPO) 80,000 Units (U) Every 4 Weeks (Q4W) vs. 40,000 U Every 2 Weeks (Q2W) in Patients with Cancer Not Receiving Chemotherapy (CT) or Radiation Therapy (RT): Final Results.

Early vs Standard Intervention with an Extended Epoetin alfa (EPO) Dose Regimen of 120,000 Units (U) Every 3 Weeks (Q3W) in Chemotherapy (CT)-Induced Anemia: Results for Elderly vs. Younger Patients in a Randomized Clinical Trial.

Erythroid Response to Epoetin alfa (EPO) 120,000 Units (U) Every Three Weeks (Q3W) Initiated Early or at a Standard Threshold in Chemotherapy-Induced Anemia (CIA).

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only